MSFT, AZN, and BLK lead Zacks' top stock picks, while TAYD and GEOS show resilience despite microcap market pressures.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), NVIDIA Corp.

ARPU increases through E5 and M365 Copilot uptake across key segments ... The company has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi and Fasenra ...

However, potentially lower sales of Lynparza and Farxiga in China, the impact of Part D redesign on U.S. oncology and slowing sales of rare disease drugs are expected to hurt the top line in 2025.

Microsoft has made a series of changes to how Microsoft 365 (M365) support updates are done, and is encouraging enterprises to move to more frequent, or even monthly, software updates.

The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.

A popular Mexican band has been fined more than $36,000 for performing songs glorifying drug cartels, authorities in the northern city of Chihuahua announced Wednesday. At a Los Tucanes de Tijuana ...

The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump administration priorities for Americans' health. The new program announced ...

FDA's long-standing accelerated approval program generally issues decisions in six months for drugs that treat life-threatening diseases. Regular drug reviews take about 10 months.

Tesla CEO Elon Musk released the results of a drug test on X to counter the New York Times’ reporting that his drug use was “more intense" in the 2024 election.

Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months. FDA's long-standing accelerated approval program generally issues ...